HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus
Oct 31, 2025 09:30 JST
- These 52-week data reinforce HTD1801's potential as a truly differentiated therapeutic to concurrently address metabolic dysregulation, inflammation, and renal progression in type 2 diabetes mellitus